Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan

Drug pricing was a reoccurring theme on the opening day of the J.P. Morgan Healthcare conference in San Francisco Jan. 9., with pharmaceutical investors increasingly concerned about the sustainability of high drug pricing in the US. With payer pushback on drug prices intensifying and many consumers and regulators outraged over high drug prices, the issue is expected to be a dominant one in 2017 that could clip sector growth.

The question of drug pricing and pricing power came up in almost every big biopharma presentation, and while executives openly acknowledged it as a festering issue that needs to be